Hiv Clinical Trials Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The HIV clinical trials market encompasses research activities across Phase I through IV studies focused on HIV and AIDS therapeutics, including antiretroviral drugs, long-acting formulations, broadly neutralizing antibodies, and HIV cure strategies. With a 2025 global market size estimated at approximately $1.64 billion, the sector represents a significant and growing segment of the broader infectious disease clinical trials space, contributing to the overall global clinical trial market projected to reach over $440 billion by 2032. Demand is sustained by the continued global HIV burden affecting tens of millions of people, combined with the need to address resistance to existing therapies and to develop interventions for hard-to-reach populations.

• •Market valued at approximately $1.64 billion in 2025, with projections to reach $2.11 billion to $2.71 billion by the early 2030s
• •HIV clinical trials are a meaningful segment of the broader global clinical trial market, which exceeded $297 billion in 2024
• •Trials span all clinical phases and cover antiretrovirals, prevention tools, and emerging cure research

A primary growth catalyst is the persistent global HIV epidemic, which continues to drive demand for novel therapies, improved drug delivery mechanisms, and long-acting treatment options that reduce pill burden. Research data from global health programs shows that recent declines in engagement across the HIV treatment and prevention cascade are creating new trial opportunities focused on retention, re-engagement, and novel delivery models. Additionally, the broader expansion of clinical trial outsourcing to contract research organizations, coupled with growing regulatory support for fast-tracked infectious disease trials, is accelerating market development.

• •Ongoing global HIV burden sustains demand for new and improved antiretroviral therapies and long-acting treatments
• •Declines in the HIV treatment and prevention cascade are prompting new research into re-engagement strategies and novel intervention models
• •Increasing reliance on contract research organizations and outsourced clinical trial services supports market expansion

The HIV clinical trials market is segmented by clinical trial phase, including Phase I safety studies, Phase II and III efficacy and large-scale pivotal trials, and Phase IV post-marketing surveillance, with Phase III trials typically representing the largest share of market spend. It is also organized by study design, interventional, observational, and expanded access, and by therapy type within the infectious disease indication, which includes HIV, hepatitis, and other co-infections relevant to immunocompromised populations.

• •Phase III pivotal trials generally account for the largest portion of HIV trial spending due to their scale and regulatory requirements
• •Geographic concentration tends to be highest in North America, Western Europe, and sub-Saharan Africa, reflecting both R&D activity and HIV prevalence
• •Expanding trial activity in emerging markets is driven by the high burden of HIV infection and improving clinical research infrastructure

What are the recent trends and outlook?

Key trends shaping the HIV clinical trials market include the growing emphasis on long-acting injectable antiretrovirals, broadly neutralizing antibody therapies, and research toward a functional HIV cure, all of which require new and specialized trial designs. Decentralized and virtual trial methodologies, accelerated during the COVID-19 pandemic, are being adopted to improve patient access and retention, particularly in underserved communities with high HIV prevalence. Looking ahead, the market is expected to maintain steady growth through the early 2030s as new therapeutic candidates advance through clinical development and as global health initiatives continue to invest in ending the HIV epidemic.

• •Long-acting injectables and HIV cure research are driving new trial demand and innovative study designs
• •Decentralized and virtual trial methodologies are improving enrollment and retention in HIV studies
• •Continued public and private investment in HIV research supports sustained market growth through 2030 and beyond